Might get a small jump tomorrow on Q1 results (which aren't expected to be anything significant but, should still be a modest increase in revenue), but after that, pending any surprise PRs on other projects, the next big date is May 29th (FDA meeting regarding different products). So, personally, I would expect some slow bleeding until then, probably down to the low 002's or high teens. Just my opinion.